Isarna Therapeutics GmbH, a Munich, Germany-based developer of TGF-β therapeutics, raised €5.5m (US$7.6m) in equity funding.
Backers included current investors AT NewTec, Global Asset Funds, and MIG Fonds.
The company intends to use the funds to expand into the US. It appointed Elizabeth Czerepak as Chief Financial Officer and Chief Business Officer to lead the new office location in New York City.
Led by Dr. Philippe Calais, Chief Executive Officer, Isarna Therapeutics develops TGF-β inhibitors that stimulate the human immune system to fight cancer and other diseases.